Table 1.

Clinical trials of antifibrotics for ILD, including RA-associated ILD (RA-ILD).

Drug	Study name	Design and population	Phase	Clinical trial identifier	Status
Nintedanib	INBUILD	Efficacy and safety of nintedanib in patients with PF-ILD	III	NCT02999178	Completed
Nintedanib	NA	A follow-up study investigating long-term treatment with nintedanib in patients with PF-ILD	III	NCT03820726	Active, not recruiting
Nintedanib	NA	An expanded access program to provide nintedanib to patients of non-IPF-ILD who have no alternative treatment possibilities	–	NCT03843892	Available
Pirfenidone	TRAIL1	Safety, tolerability, and efficacy of pirfenidone in patients with RA-ILD	II	NCT02808871	Enrollment closed
Pirfenidone	RELIEF	Efficacy and safety of pirfenidone for progressive, non-IPF lung fibrosis	II	EudraCT 2014-000861-32 DRKS00009822	Completed
Abatacept	APRIL	Safety of abatacept in RA-ILD; the investigators will perform a small clinical trial to assess the feasibility of performing a larger randomized controlled trial	–	NCT03084419	Recruiting
Tofacitinib versus Methotrexate	PULMORA	Effects of tofacitinib versus methotrexate on clinical and molecular disease activity markers in joints and lungs in early RA	IV	NCT04311567; EudraCT 2019-004179-38	Recruiting
Allogeneic bone marrow derived–mesenchymal stem cclls	NA	Safety of allogeneic bone marrow–derived mesenchymal stem cells for ILD in patients with connective tissue disease	I	NCT03929120	Recruiting

ILD, interstitial lung disease; NA, not available; PF, progressive fibrosing; RA, rheumatoid arthritis.